Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	144875-48-9
Formula :	C₁₇H₂₂N₄O₂
M.W :	314.38
SMILES Code :	CC(O)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N
Synonyms :	R848; S28463; VML-600
MDL No. :	MFCD00937759
InChI Key :	BXNMTOQRYBFHNZ-UHFFFAOYSA-N
Pubchem ID :	159603

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Human neutrophils	10 μM	3 h	To test the inhibitory effects of 6-gingerol, 8-gingerol, and 10-gingerol on neutrophil NETosis, results showed that 10 μM of 6-gingerol and 8-gingerol significantly inhibited NETosis.	PMC7934838
Mouse splenic B cells	2.5 μg/ml	2 days	To determine if T-bet+ B cells secrete CXCL10 protein. Results showed that R848 stimulation significantly increased CXCL10 secretion by B cells compared to medium alone.	PMC9357106
U87MG-LTR-Luc cells	10, 20, 40 μM	48 h	To test the effect of Resiquimod on HIV-1 LTR transactivation, results showed that Resiquimod could induce HIV-1 LTR transactivation.	PMC9627655

Mice	TLR7 agonist-induced lupus model	Intraperitoneal injection	20 mg/kg	3 times per week for 6 weeks	To evaluate the effects of 6-gingerol on NET release and autoantibody formation in a lupus mouse model, results showed that 6-gingerol significantly reduced NET levels and autoantibody levels.	PMC7934838
Mice	IFN-betaYFP/YFP mice	Intraperitoneal injection	50 nM/mouse	Single dose 24 hours before imaging	To confirm that the IFN-betaYFP/YFP mouse strain was able to report IFN-beta production under stimulation	PMC6115735
Mice	Graft-versus-host disease (GvHD) model in B6D2F1 and B6 mice	Intraperitoneal injection	25 mg/mouse	48 hours and 24 hours before, or 0 hours before transplantation	To evaluate the protective effect of R848 in the GvHD model, results showed that R848 treatment significantly improved survival rates and inhibited inflammatory cytokine production.	PMC6355498
Mice	Systemic lupus erythematosus model	Topical application	100 μg,100 μl	Days 0, 2, and 6, for a duration of 10 days	To evaluate the effect of the TLR7 agonist R848 on a systemic lupus erythematosus model in mice, showing that R848 treatment increased the frequency of CD69+CD4+ T cells, effector-memory CD4+ T cells, T follicular helper cells, and plasma cells.	PMC10971436
Mice	Normal mice	Intraperitoneal injection	50 μg	Injected on day 0 and day 2, samples collected on day 4	To investigate the effects of TLR7 agonist R848 on mouse B cells. Results showed that the proportion of T-bet+ CD11c+ B cells was significantly increased in R848-treated mice.	PMC9357106
Mice	B6.Sle1.Sle2.Sle3 (TC) and TC. Rag1-/- mice	Topical application	100 mg,100 mL	Three times a week for 2 weeks	To assess the effect of TLR7/8 activation on gut integrity, the results showed that R848 increased gut permeability in mice with lupus susceptibility genes but not in non-autoimmune mice.	PMC10358848

{[proInfo.proName]}

CAS No.: 144875-48-9

{[proInfo.proName]}

CAS No.: 144875-48-9

Product Citations Show More

Alternative Products

Product Details of Resiquimod

Safety of Resiquimod

Related Pathways of Resiquimod

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02688478	Allergies	Not Applicable	Recruiting	May 7, 2020	Canada, British Columbia ... More >> University of British columbia Recruiting Vancouver, British Columbia, Canada, V5Z 1M9 Contact: Christopher Carlsten, MD, PHD 604-875-4122 carlsten@mail.ubc.ca Principal Investigator: Christopher Carlsten, MD, MPH Less <<
NCT02637219	-		Completed	-	United States, Washington ... More >> VA Puget Sound Health Care System Seattle, Washington, United States, 98108 Less <<
NCT02687503	Respiratory Tract Infections	Not Applicable	Active, not recruiting	January 2019	United States, Wisconsin ... More >> UW Health 20 S. Park Clinic Madison, Wisconsin, United States, 53715 UW Health West Towne Clinic Madison, Wisconsin, United States, 53717 Less <<
NCT02660723	Healthy	Not Applicable	Completed	-	France ... More >> CHU de Nice, CRC, Hôpital de l'Archet 151 route de saint-antoine de ginestière Nice, Alpes-Maritimes, France, 06200 Less <<
NCT01094496	Bladder Cancer	Phase 2	Terminated(Portfolio prioritiz... More >>ation due to slow enrollment) Less <<	October 2017	United States, Arizona ... More >> BCG Oncology, PC Phoenix, Arizona, United States, 85032 United States, California University of California - San Diego La Jolla, California, United States, 92093 University of Southern California Norris Comprehensive Cancer Center LA-USC Medical Center Los Angeles, California, United States, 90033 United States, Colorado University of Colorado Cancer Center Aurora, Colorado, United States, 80045 United States, Florida University of Florida Gainesville, Florida, United States, 32610 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Iowa University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 United States, Kentucky University of Kentucky Markey Cancer Center Clinical Research Organization Lexington, Kentucky, United States, 40536-0093 United States, Maryland University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Center Buffalo, New York, United States, 14263 Weill Cornell Medical College New York, New York, United States, 10021 University of Rochester Rochester, New York, United States, 14642 SUNY Upstate Medical University Syracuse, New York, United States, 13210 Syracuse VA Medical Center Syracuse, New York, United States, 13210 United States, Pennsylvania Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT01204684	Glioma Anapla... More >>stic Astrocytoma Anaplastic Astro-oligodendroglioma Glioblastoma Less <<	Phase 2	Active, not recruiting	October 2019	United States, California ... More >> University of Los Angeles, California Los Angeles, California, United States, 90095 Less <<
NCT00175435	Hepatitis B	Phase 1 Phase 2	Completed	-	Canada, British Columbia ... More >> Vancouver General Hospital Vaccine Education Centre Vancouver, British Columbia, Canada Less <<
NCT00948961	Advanced Malignancies	Phase 1 Phase 2	Completed	-	United States, Connecticut ... More >> Yale Comprehensive Cancer Center New Haven, Connecticut, United States, 06519-1717 United States, Florida Mount Sinai Comprehensive Cancer Center Miami Beach, Florida, United States, 33140 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10017 Weill Cornell Cancer Center New York, New York, United States, 10065 United States, North Carolina Carolina BioOncology Institute, PLLC Huntersville, North Carolina, United States, 28078 United States, Oregon Providence Portland Cancer Center Portland, Oregon, United States, 97213 Less <<
NCT02090374	Allergic Rhinitis ... More >> Asthma Latent Tuberculosis Less <<	Not Applicable	Completed	-	United Kingdom ... More >> Imperial Clinical Respiratory Research Unit (ICRRU), St Mary's Hospital Paddington, London, United Kingdom, W2 1NY Less <<
NCT00115141	Warts	PHASE2	COMPLETED	-	-
NCT02126579	Melanoma Meta... More >>static Melanoma Mucosal Melanoma Less <<	Phase 1 Phase 2	Recruiting	December 2018	United States, Texas ... More >> MDAnderson Cancer Center Active, not recruiting Houston, Texas, United States, 77030 United States, Virginia University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Contact: Emily Allred, PhD 434-982-1902 eh4m@virginia.edu Contact: Alexandra Carney, MPH 434-982-6714 alc6a@virginia.edu Principal Investigator: Craig L. Slingluff, MD, M.D. Less <<
NCT01806961	-		Terminated(sponsor decision)	-	-
NCT00114920	Warts	PHASE2	COMPLETED	-	Welborn Clinic, Evansville, In... More >>diana, 47713, United States Less <<
NCT00960752	Melanoma	Phase 2	Active, not recruiting	May 2019	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00116662	Warts	PHASE2	COMPLETED	-	Arkansas, Fayetteville, Arkans... More >>as, 72703, United States\|Arkansas, Little Rock, Arkansas, 72205, United States\|Georgia, Newnan, Georgia, 30263, United States\|Illinois, Buffalo Grove, Illinois, 60089, United States\|Indiana, Lafayette, Indiana, 47904, United States\|Kansas, Wichita, Kansas, 67207, United States\|Massachusetts, Boston, Massachusetts, 02114, United States\|Missouri, St. Louis, Missouri, 63110, United States\|Utah, Layton, Utah, 84041, United States\|Vermont, Burlington, Vermont, 05401, United States Less <<
NCT01806961	-		Terminated(sponsor decision)	-	Germany ... More >> Hauttumorcentrum Charité (HTCC) Berlin, Germany Medizinisches Zentrum Bonn - Friedensplatz Bonn, Germany Hautzentrum Düsseldorf, Germany Johannes Wesling Klinikum Minden Minden, Germany KLINIKUM VEST GmbH Knappschaftskrankenhaus Recklinghausen, Germany Switzerland Universitätsspital Basel Basel, Switzerland Inselspital Bern, Switzerland Kantonsspital St.Gallen St. Gallen, Switzerland Universitaetsspital Zurich Zurich, Switzerland Less <<
NCT00117871	Warts	PHASE2	COMPLETED	-	Minnesota Clinical Study Cente... More >>r, Fridley, Minnesota, 55432, United States Less <<
NCT00117923	Warts	PHASE2	COMPLETED	-	Oregon Medical Research Center... More >>, Portland, Oregon, 97223, United States Less <<
NCT01737580	Influenza Vaccination in Senio... More >>rs Less <<	Phase 1	Completed	-	Canada, British Columbia ... More >> University of British Columbia Vancouver General Hospital Vancouver, British Columbia, Canada, V5Z 1M9 Less <<
NCT01808950	Nodular Basal Cell Carcinoma	Phase 1 Phase 2	Terminated(safety issues)	-	Germany ... More >> Hauttumorcentrum Charité (HTCC) Berlin, Germany Switzerland Universitaetsspital Zurich, Switzerland Less <<
NCT01808950	-		Terminated(safety issues)	-	-
NCT00470379	Melanoma (Skin)	Early Phase 1	Completed	-	United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT01748747	Recurrent Melanoma ... More >> Stage IIA Melanoma Stage IIB Melanoma Stage IIC Melanoma Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma Less <<	Early Phase 1	Completed	-	United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT01676831	Cutaneous T Cell Lymphoma	Phase 1 Phase 2	Unknown	-	United States, Pennsylvania ... More >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00821652	Tumors	Phase 1	Completed	-	United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT01583816	Actinic Keratosis	Phase 2	Completed	-	Germany ... More >> Hauttumorcentrum Charité (HTCC) Berlin, Germany Medizinisches Zentrum Bonn - Friedensplatz Bonn, Germany Hautzentrum Düsseldorf, Germany Johannes Wesling Klinikum Minden Minden, Germany KLINIKUM VEST GmbH Knappschaftskrankenhaus Recklinghausen, Germany Switzerland Kantonsspital Aarau Aarau, Switzerland Universitätsspital Basel Basel, Switzerland Inselspital Bern, Switzerland Kantonsspital St.Gallen St. Gallen, Switzerland Universitaetsspital Zurich Zurich, Switzerland Less <<
NCT00116675	Warts	PHASE2	COMPLETED	2025-04-06	Children's Clinic of Jonesboro... More >>, PA, Jonesboro, Arkansas, 72401, United States\|University of California - San Francisco, San Francisco, California, 94143, United States\|Longmont Clinic/Longmont Medical Research Network, Longmont, Colorado, 80501, United States\|Mercy Health Research, St. Louis, Missouri, 63141, United States\|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States\|Rhode Island Hospital - Jane Brown Building, Providence, Rhode Island, 02903, United States\|DermResearch, Inc., Austin, Texas, 78759, United States\|Alpine Pediatrics, Pleasant Grove, Utah, 84062, United States\|Walla Walla Clinic, Walla Walla, Washington, 99362, United States\|Advanced Healthcare, Milwaukee, Wisconsin, 53209, United States Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed